ESR1 and breast carcinoma: Competitive antiestrogens with selective estrogen receptor degrader/downregulator (SERD) activities with improved potencies show superior therapeutic antagonistic activities compared to 4OHT in breast cancer cells harboring Y537S or D538G ESR1 (Fanning et al., 2018b).